All In Biotech

Drug Trial Radar · NCT07933224

A Phase I Study to Evaluate the Effect of Food on the Pharmacokinetics of HS-10382 Tablets in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Feb 2027

Study completion Feb 2027

Sponsor

Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The high-fat meal food effect part adopts a single-center, randomized, open-label, two-sequence, two-period, two-way crossover dosing design. Based on the results of the high-fat meal food effect trial, the sponsor and the principal investigator will comprehensively analyze and determine whether a low-fat meal food effect trial needs to be conducted.

Conditions

  • Healthy Volunteers

Interventions

  • HS-10382Drug

    Drug: HS-10382 Comes in 40 mg tablets and taken orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of PK parameters of HS-10382: CmaxTime frame: 96 hours after administration of HS-10382
  2. Evaluation of PK parameters of HS-10382: AUC0-tTime frame: 96 hours after administration of HS-10382
  3. Evaluation of PK parameters of HS-10382: AUC0-∞Time frame: 96 hours after administration of HS-10382

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.